Omalizumab in the Treatment of Chronic Inducible Urticaria.
Sign Up to like & getrecommendations! Published in 2017 at "Actas dermo-sifiliograficas"
DOI: 10.1016/j.ad.2016.07.018
Abstract: Omalizumab is a recombinant humanized monoclonal antibody that inhibits immunoglobulin E. It has been approved for the treatment of severe asthma and chronic spontaneous urticaria refractory to other treatments. Its use in the management of… read more here.
Keywords: inducible urticaria; omalizumab treatment; treatment chronic; chronic inducible ... See more keywords
Omalizumab treatment in adolescents with chronic spontaneous urticaria: Efficacy and safety.
Sign Up to like & getrecommendations! Published in 2020 at "Allergologia et immunopathologia"
DOI: 10.1016/j.aller.2020.03.011
Abstract: BACKGROUND Omalizumab is useful as an add-on treatment in patients unresponsive to high doses of second-generation antihistamines. This study aimed to evaluate the efficacy and safety of omalizumab treatment in adolescents with refractory chronic spontaneous… read more here.
Keywords: efficacy safety; spontaneous urticaria; omalizumab treatment; treatment ... See more keywords
A case of asthma with Behcet’s disease: successful treatment with omalizumab and its effects on recurrent aphthous lesions
Sign Up to like & getrecommendations! Published in 2020 at "Immunopharmacology and Immunotoxicology"
DOI: 10.1080/08923973.2020.1789656
Abstract: Abstract Context Monoclonal antibody therapies have revolutionized the treatment of autoinflammatory-immune/genetic disease including spondylarthritis, asthma and rheumatoid arthritis. Behcet’s disease (BD) is a multi-systemic vasculitis, which is generally recurrent aphthous lesions (RAL) as well as… read more here.
Keywords: behcet disease; treatment; omalizumab treatment; disease ... See more keywords
Omalizumab treatment in a 12 year-old girl with chronic spontaneous urticaria
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Dermatological Treatment"
DOI: 10.1080/09546634.2018.1551609
Abstract: Abstract Background: Omalizumab is a recombinant humanized IgG monoclonal antibody, which binds the Fc region of free IgE prevent its binding to its high-affinity receptor (FcεR1) on mast cells and basophils. Omalizumab was approved as… read more here.
Keywords: old girl; spontaneous urticaria; omalizumab treatment; treatment ... See more keywords
Experience with Omalizumab for the treatment of chronic spontaneous urticaria in a tertiary center: real life experience
Sign Up to like & getrecommendations! Published in 2020 at "Cutaneous and Ocular Toxicology"
DOI: 10.1080/15569527.2020.1787432
Abstract: Abstract Purpose Chronic spontaneous urticaria (CSU) is defined as urticaria and/or angioedema that appears spontaneously due to known or unknown causes and lasts for at least 6 weeks. Omalizumab, an anti-IgE antibody that binds circulating free… read more here.
Keywords: omalizumab treatment; treatment; csu; real life ... See more keywords
Omalizumab treatment in combination with any other biologics: Is it really a safe duo?
Sign Up to like & getrecommendations! Published in 2023 at "Australasian Journal of Dermatology"
DOI: 10.1111/ajd.14019
Abstract: Chronic spontaneous urticaria (CSU) is a mast cell‐mediated disease, which is sometimes associated with various inflammatory disorders. Omalizumab is a commonly used biological agent, which is a recombinant, humanized, monoclonal antibody against human immunoglobulin E.… read more here.
Keywords: combination biologics; treatment combination; combination; omalizumab treatment ... See more keywords
Omalizumab for the treatment of chronic spontaneous urticaria in daily clinical practice in South Spain
Sign Up to like & getrecommendations! Published in 2018 at "Dermatologic Therapy"
DOI: 10.1111/dth.12669
Abstract: Dear Sir, Omalizumab is a recombinant humanized anti-IgE monoclonal antibody that binds the IgE molecule in the region assigned to the target cell receptor. Its main action lies in the reduction of plasma-free IgE levels… read more here.
Keywords: spontaneous urticaria; omalizumab treatment; clinical practice; chronic spontaneous ... See more keywords
Comparison between chronic spontaneous urticaria and chronic induced urticaria on the efficacy of omalizumab treatment: A systematic review and meta‐analysis
Sign Up to like & getrecommendations! Published in 2022 at "Dermatologic Therapy"
DOI: 10.1111/dth.15928
Abstract: This meta‐analysis aimed to assess the efficacy of omalizumab in the treatment of refractory‐to‐antihistamines chronic induced urticaria (CIndU) in comparison with that of refractory‐to‐antihistamines chronic spontaneous urticaria (CSU). We retrieved interventional studies and observational studies… read more here.
Keywords: cindu; meta analysis; efficacy; omalizumab treatment ... See more keywords
A retrospective analysis omalizumab treatment patterns in patients with chronic spontaneous urticaria: a real‐world study in Belgium
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the European Academy of Dermatology and Venereology"
DOI: 10.1111/jdv.15684
Abstract: Chronic spontaneous urticaria (CSU) is characterized by the repeated occurrence of persistent hives and/or angioedema for ≥6 weeks, without specific external stimuli. H1‐antihistamines have long been the standard of care of CSU, but many patients… read more here.
Keywords: spontaneous urticaria; omalizumab treatment; belgium; chronic spontaneous ... See more keywords
Cost‐effectiveness of omalizumab for the treatment of severe pediatric allergic asthma—Results of a real‐life study in Spain
Sign Up to like & getrecommendations! Published in 2023 at "Pediatric Allergy and Immunology"
DOI: 10.1111/pai.13942
Abstract: Severe pediatric allergic asthma (SPAA) induces a huge economic burden in terms of direct, indirect, and intangible costs. The use of omalizumab for the treatment of these patients has produced a significant improvement in several… read more here.
Keywords: cost; allergic asthma; omalizumab treatment; severe pediatric ... See more keywords
Comparison of the Patients with Chronic Urticaria Who Responded and Did Not Respond to Omalizumab Treatment: A Single-Center Retrospective Study
Sign Up to like & getrecommendations! Published in 2022 at "International Archives of Allergy and Immunology"
DOI: 10.1159/000526205
Abstract: Introduction: Chronic urticaria (CU) is a condition usually lasting longer than 6 weeks, with wheals and angioedema, sometimes both. Omalizumab is a recombinant humanized monoclonal IgG antibody developed against IgE. In some patients with CU,… read more here.
Keywords: omalizumab treatment; response omalizumab; count; treatment ... See more keywords